Drug intelligence / Profile preview

hyaluronic acid + clodronate

Development stage: Unknown
Lead developer: Abiogen
Modality: Small Molecules
Administration: Intraarticular

Overview

Hyaluronic acid + clodronate is a combination therapy developed by Abiogen for the treatment of osteoarthritis and joint pain. Administered via intra-articular injection, the product is classified as a medical device with an ancillary medicinal substance. Hyaluronic acid serves as a viscosupplement, restoring the rheological properties of synovial fluid to provide lubrication and shock absorption. Clodronate is a non-nitrogenous bisphosphonate that modulates bone metabolism and exerts local anti-inflammatory effects, potentially slowing joint degradation and alleviating pain. The combination is currently in Phase 2 clinical trials for osteoarthritis-related pain.

Other names: hyaluronic acid + clodronate disodium tetrahydrate

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on hyaluronic acid + clodronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyaluronic acid + clodronate.

Explore the full profile